dc.contributor.author | Abdulkadyrov, K. | |
dc.contributor.author | Sargin, D. | |
dc.contributor.author | De la Rubia, J. | |
dc.contributor.author | Ganguly, R. | |
dc.contributor.author | Diels, J. | |
dc.contributor.author | Zervas, K. | |
dc.contributor.author | Dhawan, R. | |
dc.contributor.author | Delforge, M. | |
dc.contributor.author | Samblanx, H. | |
dc.contributor.author | Hulin, C. | |
dc.contributor.author | Linderholm, M. | |
dc.date.accessioned | 2021-03-04T13:42:39Z | |
dc.date.available | 2021-03-04T13:42:39Z | |
dc.identifier.citation | Zervas K., Dhawan R., Delforge M., Samblanx H., Sargin D., Hulin C., Linderholm M., De la Rubia J., Abdulkadyrov K., Ganguly R., et al., "Bortezomib International Observational Study in Multiple Myeloma: Baseline Characteristics", CLINICAL LYMPHOMA & MYELOMA, cilt.9, 2009 | |
dc.identifier.issn | 1557-9190 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_7dd16486-d05a-4b25-b238-24f1d912437e | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/85945 | |
dc.identifier.uri | https://doi.org/10.1016/s1557-9190(11)70474-7 | |
dc.language.iso | eng | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ONKOLOJİ | |
dc.title | Bortezomib International Observational Study in Multiple Myeloma: Baseline Characteristics | |
dc.type | Makale | |
dc.relation.journal | CLINICAL LYMPHOMA & MYELOMA | |
dc.contributor.department | Theagene Anticanc Hosp Thessaloniki , , | |
dc.identifier.volume | 9 | |
dc.contributor.firstauthorID | 191228 | |